Project Grant R03HL185220
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $244K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $685,212 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop policy-relevant evidence on the scope and effects of prior authorization (PA) for cardiovascular care. The project quantifies patient exposure to PA for cardiovascular services from 2016 through 2024, identifying which patient groups experience PA barriers and measuring how PA affects service use, care...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $157,658 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, K99HL185935) to elucidate mechanical regulation of the lung gas exchange interface through investigation of how capillary endothelial cells and alveolar epithelial cells respond to biophysical strain during breathing. The award funds research into mechanically induced capillary endothelial cells (MICAPs) identified in...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $1,507,442 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulse oximeter accuracy and its impact on clinical outcomes in hospitalized patients. The ENHANCE-O2 project conducts a retrospective cohort study matching concurrent pulse oximeter readings with gold-standard arterial oxygen saturation measurements in patients with shock and acute exacerbation of COPD. The...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $177,822 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify strategies for improving allergen mitigation among adults with persistent asthma to decrease disease morbidity. The award funds career development for a candidate investigator conducting qualitative research and implementation science to address three primary aims: determining barriers and facilitators to...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $243,750 to the University of Pennsylvania on August 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a secondary analysis of the NHLBI Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial. The project will deliver research findings evaluating plasma renin as a predictive and prognostic biomarker in sepsis-induced hypotension, with...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $237,153 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance predictive modeling of hospitalizations and emergency department visits for heart failure patients in managed long-term care settings through analysis of audio-recorded telephone communications between patients and care coordinators. The project, HEAR-HEARTFELT (Identifying the Risk of Hospitalizations or...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $773,237 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the adoption, effectiveness, and system-level implications of veno-venous extracorporeal membrane oxygenation (ECMO) for treatment of severe acute respiratory failure. The research combines all-payer utilization data and private payer claims data to characterize ECMO adoption across U.S. hospitals, identify...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $718,991 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to determine the role of red blood cells in sepsis heterogeneity. The funded research investigates how red blood cells capture and deliver cell-free bacterial DNA to immune cells and distant organs during sepsis, a dysregulated host response to infection that remains a leading cause of death. The project...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...